Nucleic Acid Therapeutics Market Size and Share Outlook - Forecast Trends and Growth Analysis Report (2025-2034)
Description
The global nucleic acid therapeutics market was valued at USD 4.26 Billion in 2024 driven by advancements in genomic technologies across the globe. It is projected to grow at a CAGR of 12.84% during the forecast period of 2025-2034 and attain a market value of USD 14.26 Billion by 2034 .
Nucleic Acid Therapeutics Market Overview
Nucleic acid therapeutics utilize either synthetic or natural nucleic acids to control gene expression and address multiple ailments. ASOs, siRNAs, miRNAs, aptamers, and CRISPR/Cas9 are some of the common technologies used in this treatment. They provide a focused method for managing diseases, enabling accurate genetic intervention, particularly helpful for diseases with identifiable genetic causes like rare genetic disorders, cancers, and viral infections.
Nucleic Acid Therapeutics Market Growth Drivers
Increasing Prevalence of Genetic Disorders and Chronic Diseases Boost the Market Growth
The rising prevalence of genetic disorders, and other diseases, such as cystic fibrosis, muscular dystrophy, cancer, cardiovascular diseases, metabolic syndrome, and others are the primary factors boosting the market growth. Aberrations of DNA sequences and gene expression are often observed in these indications, for which nucleic acid therapies are a suitable solution, providing effective treatment to a wider section of the population. This is leading to an increased application of nucleic acid therapeutics, intended to combat the burden of rising morbidities.
Advancements in Genomic Technologies and Personalized Medicine to Meet Rising Nucleic Acid Therapeutics Market Demand
Advanced technologies in nucleic acid therapeutics include NGS, CRISPR/Cas9 gene editing, and bioinformatics which has further advanced the progress of these therapeutics. This makes it easier to diagnose the mutation in genes and get the right treatment for the individuals affected. The market growth is driven by the increasing demand for personalized treatments, where treatments and medications are based on a person’s genetic profile.
Increase in Clinical Trial and Research Initiatives
In August 2023, CureVac N.V. and GSK initiated a Phase 2 trial in Australia for their single and double-modified mRNA COVID-19 vaccine candidates. The study's goal is to evaluate the safety, reactogenicity, and immune responses in 415 healthy adults after successful Phase 1 results for a comparable vaccine designed for the omicron BA.1 variant.
In March 2022, Moderna, Inc. tested an experimental HIV trimer mRNA vaccine (mRNA-1574) in around 100 HIV-negative adults in a Phase 1 clinical trial. The NIAID-sponsored trial within the NIH aimed to evaluate the safety and immunogenicity of the vaccine. An NIAID grant funded the development of the vaccine, with assistance from Scripps Research and IAVI.
Nucleic Acid Therapeutics Market Trends
Several trends and developments are being observed in the market to enhance the current situation. Some of the noteworthy trends are as follows:
Integration with Nanotechnology Enhancing Market Growth
Nanotechnology is expanding the market through improvements in the delivery, stability, and performance of nucleic acid therapeutic agents. The use of lipid nanoparticles for delivery of siRNAs and mRNA vaccines in order to resist the degradation of nucleic acids is amongst the major market trends.
Expanding Applications in Oncology Boosting Market Adoption
Nucleic acid therapeutics are being increasingly employed in oncology because they can address specific cancer-related genes and signaling cascades. Techniques like antisense oligonucleotides, small interfering RNA (siRNAs), and CRISPR/Cas9 are being employed to silence oncogenes and related mutations. Such advancements are anticipated to revolutionize precision oncology, by offering personalized treatments.
Regulatory Approvals and Collaborations Enhancing Market Expansion
The nucleic acid therapeutics market is expanding due to the approval and collaborations through existing agencies such as the FDA and EMA. New drugs include Spinraza, a spinal muscular atrophy treatment, and Onpattro for transthyretin-mediated hereditary amyloidosis. These affiliations are expected to enhance the rate of development of more therapies and innovation. In September 2022, Alnylam Pharmaceuticals received the marketing approval for AMVUTTRA by the European Commission. It is an RNAi therapy for adults with stage 1 or 2 polyneuropathy caused by hereditary transthyretin-mediated amyloidosis. The authorization comes after promising 18-month findings from the HELIOS-A Phase 3 trial, with more than half of patients experiencing a stop or improvement in polyneuropathy symptoms. AMVUTTRA provides subcutaneous administration every three months or possibly twice a year.
Increasing Investment in Research and Development Driving Market Growth
The market is growing because of increased funding for research and development. There is a focus on investing in the development and identification of new drugs by pharmaceutical enterprises, biotechnology businesses, and educational establishments. It is also supported by government funding and grants for such enhancing initiatives and holds great promise for genetic disorders, cancers, chronic diseases, and others.
Nucleic Acid Therapeutics Market Segmentation
Nucleic Acid Therapeutics Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Product Type
Market Segmentation Based on End User Set to Witness Substantial Growth
Based on the end user, the market is divided into hospitals, research and academic institutes, and others. Among these, the market is expected to be dominated by research laboratories due to the rising demand for nucleic acid research and treatment interventions. These labs discover new medications and technologies, thereby nurturing new ideas for broadening their applications. Due to the tremendous interest in genetics and molecular targeted therapies, more research institutes and biotechnology companies are anticipated to adopt these technologies and impact the market landscape significantly.
Nucleic Acid Therapeutics Market Analysis by Region
Based on regions, the market report covers North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America is expected to dominate the market, driven by an immense focus on providing investments to conduct research. In addition, the presence of technically advanced infrastructure also impacts the market value positively.
European nucleic acid market comes next as a region with high regard for innovation, and noteworthy support from the healthcare regulatory authorities, aiding the implementation of neurotechnology. Growth in developing countries, especially in Asia Pacific, due to economic development, higher healthcare expenditure, and a rising population of patients suffering from genetic and chronic diseases, is encouraging market growth.
Leading Players in the Nucleic Acid Therapeutics Market
The key features of the market report include patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:
Copernicus Therapeutics Inc.
Established in 1995 and headquartered in Ticino, Switzerland, the company has a diversified product line concerning nucleic acid therapeutics. This clinical stage biopharmaceutical company has a key emphasis on leveraging gene therapy to treat rare diseases.
Silence Therapeutics PLC
Founded in 1994, the company has a presence across the United States, United Kingdom and other parts of Europe. The company is building a robust siRNAs-based pipeline for various diseases including rare diseases like Polycythemia Vera (PV) and other cardiovascular diseases. It is focused on using its mRNAi GOLD™ platform to develop innovative technologies for precise drug development.
Other companies include Sanofi S.A., Thermo Fisher Scientific Inc., Sarepta Therapeutics, Inc., Novartis AG, Merck & Co., Inc., Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and Arrowhead Pharmaceuticals, Inc.
Key Questions Answered in the Nucleic Acid Therapeutics Market
Nucleic Acid Therapeutics Market Overview
Nucleic acid therapeutics utilize either synthetic or natural nucleic acids to control gene expression and address multiple ailments. ASOs, siRNAs, miRNAs, aptamers, and CRISPR/Cas9 are some of the common technologies used in this treatment. They provide a focused method for managing diseases, enabling accurate genetic intervention, particularly helpful for diseases with identifiable genetic causes like rare genetic disorders, cancers, and viral infections.
Nucleic Acid Therapeutics Market Growth Drivers
Increasing Prevalence of Genetic Disorders and Chronic Diseases Boost the Market Growth
The rising prevalence of genetic disorders, and other diseases, such as cystic fibrosis, muscular dystrophy, cancer, cardiovascular diseases, metabolic syndrome, and others are the primary factors boosting the market growth. Aberrations of DNA sequences and gene expression are often observed in these indications, for which nucleic acid therapies are a suitable solution, providing effective treatment to a wider section of the population. This is leading to an increased application of nucleic acid therapeutics, intended to combat the burden of rising morbidities.
Advancements in Genomic Technologies and Personalized Medicine to Meet Rising Nucleic Acid Therapeutics Market Demand
Advanced technologies in nucleic acid therapeutics include NGS, CRISPR/Cas9 gene editing, and bioinformatics which has further advanced the progress of these therapeutics. This makes it easier to diagnose the mutation in genes and get the right treatment for the individuals affected. The market growth is driven by the increasing demand for personalized treatments, where treatments and medications are based on a person’s genetic profile.
Increase in Clinical Trial and Research Initiatives
In August 2023, CureVac N.V. and GSK initiated a Phase 2 trial in Australia for their single and double-modified mRNA COVID-19 vaccine candidates. The study's goal is to evaluate the safety, reactogenicity, and immune responses in 415 healthy adults after successful Phase 1 results for a comparable vaccine designed for the omicron BA.1 variant.
In March 2022, Moderna, Inc. tested an experimental HIV trimer mRNA vaccine (mRNA-1574) in around 100 HIV-negative adults in a Phase 1 clinical trial. The NIAID-sponsored trial within the NIH aimed to evaluate the safety and immunogenicity of the vaccine. An NIAID grant funded the development of the vaccine, with assistance from Scripps Research and IAVI.
Nucleic Acid Therapeutics Market Trends
Several trends and developments are being observed in the market to enhance the current situation. Some of the noteworthy trends are as follows:
Integration with Nanotechnology Enhancing Market Growth
Nanotechnology is expanding the market through improvements in the delivery, stability, and performance of nucleic acid therapeutic agents. The use of lipid nanoparticles for delivery of siRNAs and mRNA vaccines in order to resist the degradation of nucleic acids is amongst the major market trends.
Expanding Applications in Oncology Boosting Market Adoption
Nucleic acid therapeutics are being increasingly employed in oncology because they can address specific cancer-related genes and signaling cascades. Techniques like antisense oligonucleotides, small interfering RNA (siRNAs), and CRISPR/Cas9 are being employed to silence oncogenes and related mutations. Such advancements are anticipated to revolutionize precision oncology, by offering personalized treatments.
Regulatory Approvals and Collaborations Enhancing Market Expansion
The nucleic acid therapeutics market is expanding due to the approval and collaborations through existing agencies such as the FDA and EMA. New drugs include Spinraza, a spinal muscular atrophy treatment, and Onpattro for transthyretin-mediated hereditary amyloidosis. These affiliations are expected to enhance the rate of development of more therapies and innovation. In September 2022, Alnylam Pharmaceuticals received the marketing approval for AMVUTTRA by the European Commission. It is an RNAi therapy for adults with stage 1 or 2 polyneuropathy caused by hereditary transthyretin-mediated amyloidosis. The authorization comes after promising 18-month findings from the HELIOS-A Phase 3 trial, with more than half of patients experiencing a stop or improvement in polyneuropathy symptoms. AMVUTTRA provides subcutaneous administration every three months or possibly twice a year.
Increasing Investment in Research and Development Driving Market Growth
The market is growing because of increased funding for research and development. There is a focus on investing in the development and identification of new drugs by pharmaceutical enterprises, biotechnology businesses, and educational establishments. It is also supported by government funding and grants for such enhancing initiatives and holds great promise for genetic disorders, cancers, chronic diseases, and others.
Nucleic Acid Therapeutics Market Segmentation
Nucleic Acid Therapeutics Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Product Type
- RNA Interference [RNAi] and Short Interfering RNAs [siRNAs]
- Antisense Oligonucleotides (ASOs)
- Others
- Oncology
- Infectious Diseases
- Prenatal Diagnostics
- Transplantation
- Cardiovascular Disorders
- Others
- Hospitals
- Research and Academic Institutes
- Others
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Market Segmentation Based on End User Set to Witness Substantial Growth
Based on the end user, the market is divided into hospitals, research and academic institutes, and others. Among these, the market is expected to be dominated by research laboratories due to the rising demand for nucleic acid research and treatment interventions. These labs discover new medications and technologies, thereby nurturing new ideas for broadening their applications. Due to the tremendous interest in genetics and molecular targeted therapies, more research institutes and biotechnology companies are anticipated to adopt these technologies and impact the market landscape significantly.
Nucleic Acid Therapeutics Market Analysis by Region
Based on regions, the market report covers North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America is expected to dominate the market, driven by an immense focus on providing investments to conduct research. In addition, the presence of technically advanced infrastructure also impacts the market value positively.
European nucleic acid market comes next as a region with high regard for innovation, and noteworthy support from the healthcare regulatory authorities, aiding the implementation of neurotechnology. Growth in developing countries, especially in Asia Pacific, due to economic development, higher healthcare expenditure, and a rising population of patients suffering from genetic and chronic diseases, is encouraging market growth.
Leading Players in the Nucleic Acid Therapeutics Market
The key features of the market report include patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:
Copernicus Therapeutics Inc.
Established in 1995 and headquartered in Ticino, Switzerland, the company has a diversified product line concerning nucleic acid therapeutics. This clinical stage biopharmaceutical company has a key emphasis on leveraging gene therapy to treat rare diseases.
Silence Therapeutics PLC
Founded in 1994, the company has a presence across the United States, United Kingdom and other parts of Europe. The company is building a robust siRNAs-based pipeline for various diseases including rare diseases like Polycythemia Vera (PV) and other cardiovascular diseases. It is focused on using its mRNAi GOLD™ platform to develop innovative technologies for precise drug development.
Other companies include Sanofi S.A., Thermo Fisher Scientific Inc., Sarepta Therapeutics, Inc., Novartis AG, Merck & Co., Inc., Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and Arrowhead Pharmaceuticals, Inc.
Key Questions Answered in the Nucleic Acid Therapeutics Market
- What was the global nucleic acid therapeutics market value in 2024?
- What is the global nucleic acid therapeutics market forecast outlook for 2025-2034?
- What are the regional markets covered in the EMR report?
- What is the market segmentation based on the indication?
- What is the market breakup based on product type?
- What is the market breakup based on the end user?
- What are the major factors aiding the global nucleic acid therapeutics market demand?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- What are the major global nucleic acid therapeutics market trends?
- How does the rise in the geriatric population impact the market size?
- Who are the key players involved in the nucleic acid therapeutics market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
- What are the key applications within the market, and how do they influence patient outcomes?
- Which products lead the nucleic acid therapeutics market, and what factors contribute to their widespread adoption?
- Which methods are most frequently utilized in the nucleic acid therapeutics market?
- What are the driving forces behind the market's performance in North America?
- What are the unique market dynamics in Europe, and how do they compare to other regions?
Table of Contents
400 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Nucleic Acid-Based Therapeutics Market Overview
- 3.1 Global Nucleic Acid-Based Therapeutics Market Historical Value (2018-2024)
- 3.2 Global Nucleic Acid-Based Therapeutics Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Global Nucleic Acid-Based Therapeutics Market Landscape*
- 5.1 Global Nucleic Acid-Based Therapeutics Market: Developers Landscape
- 5.1.1 Analysis by Year of Establishment
- 5.1.2 Analysis by Company Size
- 5.1.3 Analysis by Region
- 5.2 Global Nucleic Acid-Based Therapeutics Market: Product Landscape
- 5.2.1 Analysis by Product Type
- 5.2.2 Analysis by Indication
- 6 Global Nucleic Acid-Based Therapeutics Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 6.2.1 Strengths
- 6.2.2 Weaknesses
- 6.2.3 Opportunities
- 6.2.4 Threats
- 6.3 PESTEL Analysis
- 6.3.1 Political
- 6.3.2 Economic
- 6.3.3 Social
- 6.3.4 Technological
- 6.3.5 Legal
- 6.3.6 Environment
- 6.4 Porter’s Five Forces Model
- 6.4.1 Bargaining Power of Suppliers
- 6.4.2 Bargaining Power of Buyers
- 6.4.3 Threat of New Entrants
- 6.4.4 Threat of Substitutes
- 6.4.5 Degree of Rivalry
- 6.5 Key Demand Indicators
- 6.6 Key Price Indicators
- 6.7 Industry Events, Initiatives, and Trends
- 6.8 Value Chain Analysis
- 7 Global Nucleic Acid-Based Therapeutics Market Segmentation (218-2034)
- 7.1 Global Nucleic Acid-Based Therapeutics Market (2018-2034) by Product Type
- 7.1.1 Market Overview
- 7.1.2 RNA Interference [RNAi] and Short Interfering RNAs [siRNAs]
- 7.1.3 Antisense Oligonucleotides (ASOs)
- 7.1.4 Others
- 7.2 Global Nucleic Acid-Based Therapeutics Market (2018-2034) by Indication
- 7.2.1 Market Overview
- 7.2.2 Oncology
- 7.2.3 Infectious Diseases
- 7.2.4 Prenatal Diagnostics
- 7.2.5 Transplantation
- 7.2.6 Cardiovascular Disorders
- 7.2.7 Others
- 7.3 Global Nucleic Acid-Based Therapeutics Market (2018-2034) by End User
- 7.3.1 Market Overview
- 7.3.2 Hospital and Clinics
- 7.3.3 Research and Academic Institute
- 7.3.4 Others
- 7.4 Global Nucleic Acid-Based Therapeutics Market (2018-2034) by Region
- 7.4.1 Market Overview
- 7.4.2 North America
- 7.4.3 Europe
- 7.4.4 Asia Pacific
- 7.4.5 Latin America
- 7.4.6 Middle East and Africa
- 8 North America Nucleic Acid-Based Therapeutics Market (218-2034)
- 8.1 North America Nucleic Acid-Based Therapeutics Market (2018-2034) by Product Type
- 8.1.1 Market Overview
- 8.1.2 RNA Interference [RNAi] and Short Interfering RNAs [siRNAs]
- 8.1.3 Antisense Oligonucleotides (ASOs)
- 8.1.4 Others
- 8.2 North America Nucleic Acid-Based Therapeutics Market (2018-2034) by Indication
- 8.2.1 Market Overview
- 8.2.2 Oncology
- 8.2.3 Infectious Diseases
- 8.2.4 Prenatal Diagnostics
- 8.2.5 Transplantation
- 8.2.6 Cardiovascular Disorders
- 8.2.7 Others
- 8.3 North America Nucleic Acid-Based Therapeutics Market (2018-2034) by End User
- 8.3.1 Market Overview
- 8.3.2 Hospital and Clinics
- 8.3.3 Research and Academic Institute
- 8.3.4 Others
- 8.4 North America Nucleic Acid-Based Therapeutics Market (2018-2034) by Country
- 8.4.1 United States of America
- 8.4.2 Canada
- 9 Europe Nucleic Acid-Based Therapeutics Market (218-2034)
- 9.1 Europe Nucleic Acid-Based Therapeutics Market (2018-2034) by Product Type
- 9.1.1 Market Overview
- 9.1.2 RNA Interference [RNAi] and Short Interfering RNAs [siRNAs]
- 9.1.3 Antisense Oligonucleotides (ASOs)
- 9.1.4 Others
- 9.2 Europe Nucleic Acid-Based Therapeutics Market (2018-2034) by Indication
- 9.2.1 Market Overview
- 9.2.2 Oncology
- 9.2.3 Infectious Diseases
- 9.2.4 Prenatal Diagnostics
- 9.2.5 Transplantation
- 9.2.6 Cardiovascular Disorders
- 9.2.7 Others
- 9.3 Europe Nucleic Acid-Based Therapeutics Market (2018-2034) by End User
- 9.3.1 Market Overview
- 9.3.2 Hospital and Clinics
- 9.3.3 Research and Academic Institute
- 9.3.4 Others
- 9.4 Europe Nucleic Acid-Based Therapeutics Market (2018-2034) by Country
- 9.4.1 United Kingdom
- 9.4.2 Germany
- 9.4.3 France
- 9.4.4 Italy
- 9.4.5 Others
- 10 Asia Pacific Nucleic Acid-Based Therapeutics Market (218-2034)
- 10.1 Asia Pacific Nucleic Acid-Based Therapeutics Market (2018-2034) by Product Type
- 10.1.1 Market Overview
- 10.1.2 RNA Interference [RNAi] and Short Interfering RNAs [siRNAs]
- 10.1.3 Antisense Oligonucleotides (ASOs)
- 10.1.4 Others
- 10.2 Asia Pacific Nucleic Acid-Based Therapeutics Market (2018-2034) by Indication
- 10.2.1 Market Overview
- 10.2.2 Oncology
- 10.2.3 Infectious Diseases
- 10.2.4 Prenatal Diagnostics
- 10.2.5 Transplantation
- 10.2.6 Cardiovascular Disorders
- 10.2.7 Others
- 10.3 Asia Pacific Nucleic Acid-Based Therapeutics Market (2018-2034) by End User
- 10.3.1 Market Overview
- 10.3.2 Hospital and Clinics
- 10.3.3 Research and Academic Institute
- 10.3.4 Others
- 10.4 Asia Pacific Nucleic Acid-Based Therapeutics Market (2018-2034) by Country
- 10.4.1 China
- 10.4.2 Japan
- 10.4.3 India
- 10.4.4 ASEAN
- 10.4.5 Australia
- 10.4.6 Others
- 11 Latin America Nucleic Acid-Based Therapeutics Market (218-2034)
- 11.1 Latin America Nucleic Acid-Based Therapeutics Market (2018-2034) by Product Type
- 11.1.1 Market Overview
- 11.1.2 RNA Interference [RNAi] and Short Interfering RNAs [siRNAs]
- 11.1.3 Antisense Oligonucleotides (ASOs)
- 11.1.4 Others
- 11.2 Latin America Nucleic Acid-Based Therapeutics Market (2018-2034) by Indication
- 11.2.1 Market Overview
- 11.2.2 Oncology
- 11.2.3 Infectious Diseases
- 11.2.4 Prenatal Diagnostics
- 11.2.5 Transplantation
- 11.2.6 Cardiovascular Disorders
- 11.2.7 Others
- 11.3 Latin America Nucleic Acid-Based Therapeutics Market (2018-2034) by End User
- 11.3.1 Market Overview
- 11.3.2 Hospital and Clinics
- 11.3.3 Research and Academic Institute
- 11.3.4 Others
- 11.4 Latin America Nucleic Acid-Based Therapeutics Market (2018-2034) by Country
- 11.4.1 Brazil
- 11.4.2 Argentina
- 11.4.3 Mexico
- 11.4.4 Others
- 12 Middle East and Africa Nucleic Acid-Based Therapeutics Market (218-2034)
- 12.1 Middle East and Africa Nucleic Acid-Based Therapeutics Market (2018-2034) by Product Type
- 12.1.1 Market Overview
- 12.1.2 RNA Interference [RNAi] and Short Interfering RNAs [siRNAs]
- 12.1.3 Antisense Oligonucleotides (ASOs)
- 12.1.4 Others
- 12.2 Middle East and Africa Nucleic Acid-Based Therapeutics Market (2018-2034) by Indication
- 12.2.1 Market Overview
- 12.2.2 Oncology
- 12.2.3 Infectious Diseases
- 12.2.4 Prenatal Diagnostics
- 12.2.5 Transplantation
- 12.2.6 Cardiovascular Disorders
- 12.2.7 Others
- 12.3 Middle East and Africa Nucleic Acid-Based Therapeutics Market (2018-2034) by End User
- 12.3.1 Market Overview
- 12.3.2 Hospital and Clinics
- 12.3.3 Research and Academic Institute
- 12.3.4 Others
- 12.4 Middle East and Africa Nucleic Acid-Based Therapeutics Market (2018-2034) by Country
- 12.4.1 Saudi Arabia
- 12.4.2 United Arab Emirates
- 12.4.3 Nigeria
- 12.4.4 South Africa
- 12.4.5 Others
- 13 Regulatory Framework
- 13.1 Regulatory Overview
- 13.2 US FDA
- 13.3 EU EMA
- 13.4 INDIA CDSCO
- 13.5 JAPAN PMDA
- 13.6 Others
- 14 Patent Analysis
- 14.1 Analysis by Type of Patent
- 14.2 Analysis by Publication Year
- 14.3 Analysis by Issuing Authority
- 14.4 Analysis by Patent Age
- 14.5 Analysis by CPC Analysis
- 14.6 Analysis by Patent Valuation
- 14.7 Analysis by Key Players
- 15 Clinical Trials Analysis
- 15.1 Analysis by Trial Registration Year
- 15.2 Analysis by Trial Status
- 15.3 Analysis by Trial Phase
- 15.4 Analysis by Therapeutic Area
- 15.5 Analysis by Geography
- 16 Grants Analysis
- 16.1 Analysis by Year
- 16.2 Analysis by Amount Awarded
- 16.3 Analysis by Issuing Authority
- 16.4 Analysis by Grant Application
- 16.5 Analysis by Funding Institute
- 16.6 Analysis by NIH Departments
- 16.7 Analysis by Recipient Organization
- 17 Funding and Investment Analysis
- 17.1 Analysis by Funding Instances
- 17.2 Analysis by Type of Funding
- 17.3 Analysis by Funding Amount
- 17.4 Analysis by Leading Players
- 17.5 Analysis by Leading Investors
- 17.6 Analysis by Geography
- 18 Strategic Initiatives
- 18.1 Analysis by Partnership Instances
- 18.2 Analysis by Type of Partnership and Collaborations
- 18.3 Analysis by Joint Ventures
- 18.4 Analysis by Leading Players
- 18.5 Analysis by Geography
- 19 Supplier Landscape
- 19.1 Market Share Analysis, By Region (Top 5 Companies)
- 19.2 Copernicus Therapeutics Inc.
- 19.2.1 Financial Analysis
- 19.2.2 Product Portfolio
- 19.2.3 Demographic Reach and Achievements
- 19.2.4 Company News and Development
- 19.2.5 Certifications
- 19.3 Silence Therapeutics PLC
- 19.3.1 Financial Analysis
- 19.3.2 Product Portfolio
- 19.3.3 Demographic Reach and Achievements
- 19.3.4 Company News and Development
- 19.3.5 Certifications
- 19.4 Sanofi S.A.
- 19.4.1 Financial Analysis
- 19.4.2 Product Portfolio
- 19.4.3 Demographic Reach and Achievements
- 19.4.4 Company News and Development
- 19.4.5 Certifications
- 19.5 Thermo Fisher Scientific Inc.
- 19.5.1 Financial Analysis
- 19.5.2 Product Portfolio
- 19.5.3 Demographic Reach and Achievements
- 19.5.4 Company News and Development
- 19.5.5 Certifications
- 19.6 Sarepta Therapeutics, Inc.
- 19.6.1 Financial Analysis
- 19.6.2 Product Portfolio
- 19.6.3 Demographic Reach and Achievements
- 19.6.4 Company News and Development
- 19.6.5 Certifications
- 19.7 Novartis AG
- 19.7.1 Financial Analysis
- 19.7.2 Product Portfolio
- 19.7.3 Demographic Reach and Achievements
- 19.7.4 Company News and Development
- 19.7.5 Certifications
- 19.8 Merck & Co., Inc.
- 19.8.1 Financial Analysis
- 19.8.2 Product Portfolio
- 19.8.3 Demographic Reach and Achievements
- 19.8.4 Company News and Development
- 19.8.5 Certifications
- 19.9 Alnylam Pharmaceuticals, Inc.
- 19.9.1 Financial Analysis
- 19.9.2 Product Portfolio
- 19.9.3 Demographic Reach and Achievements
- 19.9.4 Company News and Development
- 19.9.5 Certifications
- 19.10 Ionis Pharmaceuticals, Inc.
- 19.10.1 Financial Analysis
- 19.10.2 Product Portfolio
- 19.10.3 Demographic Reach and Achievements
- 19.10.4 Company News and Development
- 19.10.5 Certifications
- 19.11 Arrowhead Pharmaceuticals, Inc.
- 19.11.1 Financial Analysis
- 19.11.2 Product Portfolio
- 19.11.3 Demographic Reach and Achievements
- 19.11.4 Company News and Development
- 19.11.5 Certifications
- 20 Global Nucleic Acid-Based Therapeutics Market – Distribution Model (Additional Insight)
- 20.1 Overview
- 20.2 Potential Distributors
- 20.3 Key Parameters for Distribution Partner Assessment
- 21 Key Opinion Leaders (KOL) Insights (Additional Insight)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
